The European Medicines Agency's Committee for Medicinal Products for Human Use recommended the approval of Celgene's Revlimid, or lenalidomide, to treat certain patients with myelodysplastic syndromes. EMA could release its approval decision within two to three months. Revlimid is already sold as a treatment for multiple myeloma in Europe and the U.S.

Full Story:

Related Summaries